Arrêt de service programmé du vendredi 10 juin 16h jusqu’au lundi 13 juin 9h. Pour en savoir plus
Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Onsets of progression and second treatment determine survival of patients with symptomatic Waldenstrom macroglobulinemia

Abstract : Few reports assess prognosis during follow-up of patients with symptomatic Waldenstrom macroglobulinemia (WM). In 121 WM patients treated between 1993 and 2016, we analyzed the prognostic role during the clinical course of the initial International Prognostic Scoring System for WM (IPSSWM). Then, we assessed onset of response, progression, and second treatment initiation coded as time-dependent covariates. High-risk IPSSWM was an adverse prognostic factor for survival after first treatment initiation (SAFTI). Nevertheless, the corresponding Dxy concordance index obtained in multiple landmark analyses decreased from 0.24 to 0.08 during the first 6 years, in accordance with a departure from the proportional hazard assumption. By contrast with onset of response (whatever its level), onset of progression and initiation of second-line treatment retained prognostic value for SAFTI (P = .02 and P = .006, respectively). These findings were confirmed in cause-specific Cox models for deaths related to WM, but not for unrelated deaths. Time to progression after first-line treatment and time to initiation of second-line treatment had no prognostic value for survival after these 2 events. These results were confirmed in an independent series of 119 patients homogeneously treated with chemoimmunotherapy. Finally, after second-line and third-line treatment, onset of progression had significant prognostic value for subsequent risk of related death only. Thus, taking initial IPSSWM and delayed response to treatment into account, only onset of progression and second treatment initiation provided additional prognostic information for SAFTI. Therefore, progression-free survival or time to next treatment may be satisfactory surrogate end points of SAFTI in WM.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal-u-picardie.archives-ouvertes.fr/hal-03605022
Contributeur : Louise Dessaivre Connectez-vous pour contacter le contributeur
Soumis le : jeudi 10 mars 2022 - 17:28:44
Dernière modification le : mercredi 23 mars 2022 - 15:51:13

Lien texte intégral

Identifiants

Citation

Stephanie Guidez, Julien Labreuche, Elodie Drumez, Loic Ysebaert, Jana Bakala, et al.. Onsets of progression and second treatment determine survival of patients with symptomatic Waldenstrom macroglobulinemia. BLOOD ADVANCES, 2018, 2 (22), pp.3102-3111. ⟨10.1182/bloodadvances.2018021287⟩. ⟨hal-03605022⟩

Partager

Métriques

Consultations de la notice

7